Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 233

The DOI matches its Crossref record.

Cancer nanomedicine: is targeting our target?

Open access
Lammers, Twan, Kiessling, Fabian, Ashford, Marianne, Hennink, Wim, Crommelin, Daan, Storm, Gert·2016·Nature Reviews Materials

Abstract

Nanomedicine may have a delivery problem. Rigorous, realistic and holistic rethinking is needed to improve nanomedicine performance and increase patient benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/natrevmats.2016.69

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 5

  1. Torrice, M. Does nanomedicine have a delivery problem? ACS Cent. Sci. 2, 434–437 (2016). · DOI · Paper page
  2. Venditto, V.J. & Szoka, F.C. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliv. Rev. 65, 80–88 (2013). · DOI · Paper page
  3. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016). · DOI · Paper page
  4. Lammers, T., Rizzo, L.Y., Storm, G. & Kiessling, F. Personalized nanomedicine. Clin. Cancer Res. 18, 4889–4894 (2012). · DOI · Paper page
  5. Tietjen, G.T. & Saltzman, W.M. Nanomedicine gets personal. Sci. Transl. Med. 7, 314fs47 (2015). · DOI

Cited by

See all 233

Metadata

Authors
Lammers, T., Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., & Storm, G.
Venue
Nature Reviews Materials
Published
2016-09-07
Volume
1
Issue
9
ISSN
2058-8437 (ISSN-L)
OpenAlex
W2510123569
Cited by
233
References
0
FWCI
10.78
Type
journal article
Language
en
Update notices
erratum (2016-09-09)
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer nanomedicine: is targeting our target? https://app.cochat.ai/papers/10.1038/natrevmats.2016.69
The paper
Lammers, T., Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., & Storm, G. (2016). Cancer nanomedicine: is targeting our target? Nature Reviews Materials. https://doi.org/10.1038/natrevmats.2016.69

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.